Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder

Pharmacogenomics

Volumn 16, Issue 17, 2015, Pages 1919-1929

  MacIukiewicz, Malgorzata ^a   Marshe, Victoria S ^a,b   Tiwari, Arun K ^a   Fonseka, Trehani M ^a,c,d   Freeman, Natalie ^a   Rotzinger, Susan ^c,e   Foster, Jane A ^c,f   Kennedy, James L ^a,b,e   Kennedy, Sidney H ^c,d,e   Müller, Daniel J ^a,b,e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

BDNF; cytokines; depression; duloxetine; IL 6; inflammation; placebo; treatment response; TSPO

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PLACEBO; 4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; IL6 PROTEIN, HUMAN; TSPO PROTEIN, HUMAN;

ADULT; ARTICLE; BDNF GENE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; IL 1BETA GENE; IL 2 GENE; IL 6 GENE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PSYCHOLOGICAL RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TSPO GENE; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GENETIC VARIATION; GENETICS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DULOXETINE HYDROCHLORIDE; FEMALE; GENETIC VARIATION; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, GABA; TREATMENT OUTCOME;

EID: 84947916052     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.136     Document Type: Article

References (61)

1. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J. Affect. Disord. 169, 15-20 (2014).
2. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharm. 22, 239-258 (2012).
3. GENDEP Investigators, MARS Investigators, STAR D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 170(2), 207-217 (2013).
4. Kovacs D, Gonda X, Petschner P et al. Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. Ann. Gen. Psychiatry 13, 17 (2014).
5. Gvozdic K, Brandl JE, Taylor LD, Muller JD. Genetics and personalized medicine in antidepressant treatment. Curr. Pharm. Des. 18, 5853-5878 (2012).
6. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav. Immun. 31, 31-47 (2013).
7. Eller T, Vasar V, Shlik J, Maron E. The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr. Opin. Investig. Drugs 10, 638-643 (2009).
8. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741 (2009).
9. Hannestad J, DellaGioia N, Gallezot JD et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C] PBR28 PET study. Brain Behav. Immun. 33, 131-138 (2013).
10. Tadi A, Rujescu D, Mler MJ et al. Association analysis between variants of the interleukin-1 and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr. Dis. Treat. 4, 269-276 (2008).
11. Baune BT, Dannlowski U, Domschke K et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol. Psychiatry 67, 543-549 (2010).
12. O'Brien SM, Scully P, Fitzgerald P et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41, 326-331 (2007).
13. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167, 555-564 (2010).
14. Dell'osso B, Camuri G, Dobrea C et al. Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups. Clin. Pract. Epidemiol. Ment. Health 8, 120-125 (2012).
15. Houston JP, Kohler J, Ostbye KM et al. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder. Psychiatry Res. 189, 475-477 (2011).
16. Perlis RH, Fijal B, Dharia S et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol. Psychiatry 67, 1110-1113 (2010).
17. Perlis RH, Fijal B, Adams DH et al. Variation in catechol-Omethyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry 65, 785-791 (2009).
18. Perlis RH, Fijal B, Dharia S, Houston JP. Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. Pharmacogenomics J. 13, 280-285 (2013).
19. Fornaro M, Escelsior A, Rocchi G et al. BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurol. Sci. 36(5), 729-734 (2014).
20. Khan A, Bhat A, Kolts R et al. Why has the antidepressantplacebo difference in antidepressant clinical trials diminished over the past three decades CNS Neurosci. Ther. 16, 217-226 (2010).
21. Serretti A, Kato M, De Ronchi D et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12, 247-257 (2006).
22. Tiwari AK, Zai CC, Sajeev G et al. Analysis of 34 candidate genes in bupropion and placebo remission. Int. J. Neuropsychopharmacol. 16, 771-781 (2013).
23. Leuchter AF, McCracken JT, Hunter AM et al. Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J. Clin. Psychopharmacol. 29, 372-377 (2009).
24. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287, 1840-7 (2002).
25. Clinical Trials Database: NCT00635219. https://clinicaltrials.gov
26. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur. Neuropsychopharmacol. 22, 482-491 (2012).
27. Clinical Trials database: NCT01140906. https://clinicaltrials.gov
28. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetinereferenced study in the acute treatment of adult patients with major depressive disorder. Int. Clin. Psychopharmacol. 29, 138-149 (2014).
29. Clinical Trials Database: NCT00599911. https://clinicaltrials.gov
30. American Psychiatric Association. In:Mood Disorders Diagnostic And Statistical Manual Of Mental Disorders (4th Edition). Ross R, First MB (Eds). Washington DC, USA (American Psychiatric Association 2000).
31. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
32. Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J. Affect. Disord. 76, 127-135 (2003).
33. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
34. Fonseka TM, Tiwari AK, Gonlves VF et al. The role of genetic variation across IL-1beta, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. World J. Biol. Psychiatry 16, 45-56 (2015).
35. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).
36. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
37. Benjamini YH. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 57, 289-300 (1995).
38. RC Team. R: A Language and Environment for Statistical Computing. 3.1.2 edn (R Foundation for Statistical Computing, Vienna, Austria 2014). www.r-project.org/
39. Weisberg S, Fox J. An R Companion to Applied Regression. J. Biopharm. Stat. 22(2), 418-419 (2012).
40. Torchiano M. effsize: Efficient Effect Size Computation. 0.5.4. edn (2015). http://finzi.psych.upenn.edu
41. De Micheaux PL, Tran VA. PoweR: Computation of Power and Level Tables for Hypothesis Tests. Vol. 1.0.4 (2014). http://r.meteo.uni.wroc.pl
42. Gene Ontology Consortium. Gene Ontology Consortium: going forward. Nucleic Acids Res. 43, D1049-D1056 (2015).
43. Lin HC, Liu CC, Kang WY et al. Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol. Int. 83, 463-470 (2009).
44. Zhao XM, Gao YF, Zhou Q et al. Relationship between interleukin-6 polymorphism and susceptibility to chronic hepatitis B virus infection. World J. Gastroenterol. 19, 6888-6893 (2013).
45. Chen M, Li T, Lin S et al. Association of Interleukin 6 gene polymorphisms with genetic susceptibilities to spastic tetraplegia in males: a case-control study. Cytokine 61, 826-830 (2013).
46. Bi D, Chen M, Zhang X et al. The association between sexrelated interleukin-6 gene polymorphisms and the risk for cerebral palsy. J. Neuroinflammation 11, 100 (2014).
47. Xie GQ, Yu H, Chen JZet al. [Relationship of genetic variants and cardiovascular risk factors with interleukin-6 and interleukin-10 secreted by monocytes]. Beijing Da Xue Xue Bao 46, 589-595 (2014).
48. Joynt KE, Whellan DJ, O'Connor CM. Depression and cardiovascular disease: mechanisms of interaction. Biol. Psychiatry 54, 248-261 (2003).
49. Baune BT, Stuart M, Gilmour A et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. Transl. Psychiatry 2, e92 (2012).
50. Lett HS, Blumenthal JA, Babyak MA et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom. Med. 66, 305-315 (2004).
51. Karaivazoglou K, Iconomou G, Triantos C et al. Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Ann. Hepatol. 9, 419-427 (2010).
52. Zignego AL, Cozzi A, Carpenedo R et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig. Liver Dis. 39(Suppl. 1), S107-S111 (2007).
53. Cozzi A, Zignego AL, Carpendo R et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J. Viral. Hepat. 13, 402-408 (2006).
54. Yang JJ, Wang N, Yang C et al. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol. Psychiatry 77, e19-e20 (2015).
55. Rethorst CD, Toups MS, Greer TL et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry 18, 1119-1124 (2013).
56. Alian S, Masoudzadeh A, Khoddad T et al.Depression in hepatitis B and C, and its correlation with hepatitis drugs consumption (interfron/lamivodin/ribaverin). Iran. J. Psychiatry Behav. Sci. 7, 24-29 (2013).
57. Huang YW, Hu JT, Hu FC et al. Biphasic pattern of depression and its predictors during pegylated interferonbased therapy in chronic hepatitis B and C patients. Antivir. Ther. 18, 567-573 (2013).
58. Evon DM, Ramcharran D, Belle SH et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am. J. Gastroenterol. 104, 2949-2958 (2009).
59. Malyszczak K , Inglot M, Pawowski T et al. [Depressive symptoms during treatment with interferon alpha for HCV infection-preliminary report]. Psychiatr. Pol. 40, 799-808 (2006).
60. Golub ET, Latka M, Hagan H et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J. Urban Health 81, 278-290 (2004).
61. Zajkowska ZE, Englund A, Zunszain PA. Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. Pharmacogenomics 15, 687-698 (2014).